The program includes the COGENT-1 and COGENT-2 trials. COGENT (Clopidogrel and the optimization of gastrointestinal events trial) trials are designed to measure the incidence of upper gastrointestinal bleeding and ulcers in patients who take CGT-2168 and aspirin compared with patients who take clopidogrel and aspirin.
CGT-2168 is a unique once-daily pill that combines the antiplatelet agent clopidogrel (currently marketed by Bristol-Myers Squibb and Sanofi-Aventis as Plavix with a gastroprotectant (omeprazole). The product is designed to significantly reduce the gastrointestinal side effects commonly associated with antiplatelet therapy.
Mark Goldsmith, president and CEO of Cogentus Pharmaceuticals, said: “Our goal is to improve the safety and tolerability of antiplatelet therapy by significantly reducing gastrointestinal adverse events, including bleeding, to help patients stay on their intended antiplatelet treatment. We believe CGT-2168 may be a significant advance that will preserve and extend the cardiovascular benefits of antiplatelet therapy.”